Trioxifene


Trioxifene , or as the salt trioxifene mesylate, is a selective estrogen receptor modulator with competitive binding activity against estradiol for the ERα and antagonistic activity against ERα-mediated gene expression, that was under preclinical and clinical development by Eli Lilly and Company for breast cancer and prostate cancer, but was abandoned.